Bill Gates population control with vaccines? And so who

New Post Public Reply Private Reply Replies (1) Message Board
wowhappens28 Lmcat #62429
369
Bill Gates population control with vaccines? And so who has more kids, unvaccinated illegal immigrants? Gates video at the bottom.

MMR Vaccine’s Poison Pill: Mumps After Puberty, Reduced Testosterone and Sperm Counts

https://childrenshealthdefense.org/news/vacci...rm-counts/

By Robert F. Kennedy, Jr., Chairman of the Board, Children’s Health Defense

Across the country, frenzied legislators are responding to the pharmaceutical industry’s orchestrated fear campaign around measles by seeking to impose further mandating of Merck’s measles, mumps and rubella (MMR) vaccine. Although ongoing mumps outbreaks involving thousands of at-risk adolescents and young adults completely dwarf the number of measles cases, no one is covering the mumps story—because it will expose the fact that Merck has been in court for over eight years due to scientists blowing the whistle on Merck’s fabrication and falsification of the effectiveness of the mumps component of its MMR vaccine. Instead of punishing Merck for its chicanery, legislatures are rewarding the company by making it impossible to refuse Merck’s profitable vaccine, subjecting a generation of American children to the risk of serious complications from mumps infection at an age that nature never intended.

When younger children experience mumps, the virus is relatively harmless; infected children often exhibit no symptoms. When mumps strikes adolescents or adults, on the other hand, the infection can cause far more serious adverse effects, including inflammation of various organs (brain, pancreas, ovaries and testicles)—as well as damage to male fertility.

Inflammation of one or both testicles (a condition called orchitis) occurs in approximately one in three post-pubertal men who get mumps and can contribute to sperm defects and subfertility as well as impairing the function of cells that produce testosterone. An estimated 30% to 87% of men with bilateral orchitis induced by mumps experience full-blown infertility—a major cause for concern given the significant declines in male fertility observed over the past several decades. Thus, it appears that Merck’s vaccine, instead of protecting children, not only delays onset of disease to later age cohorts but has the potential to cause serious and permanent injury.

Merck and mumps vaccines
Let’s look at a quick history of mumps and MMR vaccination in the United States. The Food and Drug Administration (FDA) licensed Merck’s initial mumps-only vaccine in 1967. In 1971, Merck introduced its first combination MMR vaccine, followed by the MMR-II vaccine in 1978 (which repurposed the rubella component) and the MMR-plus-varicella (MMRV) ProQuad vaccine in 2005. Since the initial 1967 vaccine, Merck has enjoyed a unique monopoly position in the U.S. market for mumps and MMR vaccines, with combined sales of MMR-II and ProQuad bringing in over $720 million in 2014 alone. Merck consistently places in the top five pharmaceutical companies globally, and the market valued its stocks at a seven-year high as of late 2018.

… Merck has willfully and illegally maintained its monopoly through ongoing manipulation and by representing to the public and government agencies a falsely inflated efficacy rate for its Mumps Vaccine.
In order to score the lucrative MMR monopoly, Merck needed to satisfy the FDA that all three components of the combination vaccine could achieve 95% efficacy, but the mumps portion was bedeviling. In fact, as alleged in a lawsuit filed by two senior Merck scientists in 2010 under the False Claims Act, the company has known since the late 1990s that the mumps component of the MMR is “far less” than 95% effective. A 2005 study published in Vaccine estimated the effectiveness of mumps vaccination to be closer to 69%, and the authors noted that their results were consistent with other studies.

The two whistleblowers assert in the lawsuit—which is reportedly headed to trial sometime this year—that Merck has “willfully and illegally maintained its monopoly” through “ongoing manipulation” and by “representing to the public and government agencies a falsely inflated efficacy rate for its Mumps Vaccine.” Specifically, the two scientists claim that Merck executives ordered them to use “rigged” methodologies, including taking antibodies from rabbits and adding them to human blood vials, in order to gull regulators into assuming an antibody response robust and durable enough to merit licensing. When those “enhanced” tactics did not achieve Merck’s “fabricated [95%] efficacy rate,” the whistleblowers allege, the company resorted to simply falsifying the test data and engaging in other fraudulent activities.

The fact that we have mumps showing up in highly immunized populations likely reflects something about the effectiveness of the vaccine.
Unprotected adolescents and young adults
The poor performance of the MMR’s mumps component and the doubtful “durability” of mumps-specific immunity following vaccination are of concern. In fact, we are already living with the legacy of this badly flawed vaccine. Rather than protecting a generation of American children from mumps infection in childhood, the vaccine has merely postponed the onset of the virus to older age groups, putting them at much greater risk. Researchers confirm an increase in the median age of mumps patients, a surge in the size and number of mumps outbreaks in highly vaccinated populations and higher rates of complications—including orchitis.

Across the country, galloping mumps epidemics have been ravishing an older generation of vaccinated individuals. The Centers for Disease Control and Prevention (CDC) reported 150 outbreaks (9,200 cases) in the year and a half from January 2016 to June 2017, affecting “schools, universities, athletics teams and facilities, church groups, workplaces, and large parties and events.”

Over the past several years, the number of college campuses reporting mumps outbreaks has exploded—at institutions ranging from Harvard and Temple to Syracuse, Louisiana State and Indiana universities. At the University of Missouri, which in 2016 reported 193 mumps cases on campus, the health center director reported not having seen anything like it “in her 31 years at the school.” Commenting on the fact that all of the afflicted students had had the requisite two doses of MMR, she noted, “The fact that we have mumps showing up in highly immunized populations likely reflects something about the effectiveness of the vaccine.”

The mumps virus has also made a “comeback” in other settings where younger adults congregate. For example, a naval ship deployed to the Persian Gulf, the USS Fort McHenry, has been unable to come ashore since early January because of a mumps contagion that has devastated its crew—even though the military vaccinates all personnel against the virus and despite the Navy having immediately subjected the crew in question to another MMR booster. News accounts have declined to comment on mumps complications but describe the quarantine as “a morale killer” for crew members who are accustomed to having monthly port calls. Infection control protocols stipulate that the Navy cannot declare the situation “under control” until “50 days after the last affected service member recovers.”

Endangering rather than protecting youth
All of these cohorts are part of an age group that should never get mumps. As Children’s Health Defense recently noted, whereas “flares of illness in vaccinated groups should prompt some serious questions about vaccine failure,” legislators and government agencies “are displaying a dangerous indifference to vaccination’s unintended consequences.” Dancing to puppet strings manipulated by Merck, legislators across the country are trying to foist even harsher MMR mandates on unwilling Americans, dooming a generation of children to the serious risks of late-onset mumps infections.

https://www.youtube.com/watch?v=Gc16H3uHKOA

Scroll down for more posts ▼

Top 10 Most Recent News Articles

A2Gold Divests Bolo in Strategic $1.5 Million Sale

Updated Category News Views 35

A2Gold Shifts Focus, Cashes in on Bolo You catch wind of A2Gold's latest move, and it's not just some footnote. This outfit's unloading its interest in the Bolo Gold Project over in Nye County, Nevada, to Super Gold Mining Corp. You'd think they're just getting rid of excess baggage, but there's more under the hood. Breakdown of the Deal The transaction's worth C$1.5...

Continue Reading
Ashling's New Feat: Microsoft Recognition in AI

Updated Category News Views 37

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

Continue Reading
Geolava, Vaidio, Sensoneo Triumph in Texas Pitch Contest

Updated Category News Views 0

North Texas Lights the Innovation Torch Big moves are happening in North Texas, with a pitch competition that's more than just smoke and mirrors. We're talking about an arena where regional challenges meet cutting-edge solutions, and out of a global mix, Geolava, Vaidio, and Sensoneo snagged the 2026 North Texas Connected Innovation Pitch Contest crown. It's high stakes...

Continue Reading
Minesto Charts Bold Tides with Dragon Farms Funding

Updated Category News Views 77

Minesto’s making waves, folks, and it ain’t just its tech splashing around. This Swedish tidal power ace is strutting on the global stage, flexing some serious muscle with projects that mean business. From the dragon-taming Faroe Islands to the Irish coasts, they’re pushing the envelope on tidal energy, and investors might wanna take note. Dragon Power Unleashed:...

Continue Reading
Pozdeutinurad Phase 3 Success Impact on Sobi and Market

Updated Category News Views 60

Pozdeutinurad's Phase 3 Triumph Ah, the life of biotech—constant ups and downs, but when you hit a homerun, it feels like the market stands still for a second. Pozdeutinurad's recent Phase 3 REDUCE-2 study results are one of those moments for Swedish Orphan Biovitrum AB, or Sobi for short. This study showed some seriously compelling data: clinically meaningful and...

Continue Reading
Shield HealthCare Expands Access for Astiva Members

Updated Category News Views 46

Opening Up New Avenues for Health Care Here's a nugget from the healthcare sector that's worth chewing on. Shield HealthCare has just inked a deal with Astiva Health that opens the floodgates for eligible members in Southern California to access medical supplies through Shield's extensive network. It's a big move that aims to make health management a tad easier for folks...

Continue Reading
HR HealthCare Foundation: New Chapter of Giving

Updated Category News Views 62

HR HealthCare Reaffirms Commitment Through New Foundation The corporate world didn't see this one coming. On October 29, 2026, HR HealthCare, a stalwart in the healthcare products arena, has decided to double down on its benevolent side by establishing the HR HealthCare Foundation. It ain't just about selling widgets anymore; it's about making a genuine impact outside the...

Continue Reading
Life Time's Q3 2026 Results Highlight Solid Growth

Updated Category News Views 49

Life Time Rolls On With Strong Q3 Performance Sometimes the market hands you pure gold, and that's what Life Time (NYSE: LTH) has right now. They didn't just have a decent quarter; they outright nailed it with a $893.5 million total revenue haul—a hefty 14.2% rise from the prior year. What's driving this ship? Solid growth in membership dues and dynamic personal...

Continue Reading
5GAA Brings Cutting-Edge Tech to India’s Roads

Updated Category News Views 21

India's Mobility Challenge: A Crossroads for Innovation When it comes to road networks, India isn't playing with a small deck—the nation’s highways and byways stretch across vast and complicated landscapes. It's like a massive puzzle we're trying to solve. The bigwigs from the 5G Automotive Association (5GAA) just wrapped up their gig in New Delhi, showing off tech...

Continue Reading
ACTEC Welcomes 55 New Fellows: A Closer Look

Updated Category News Views 99

Coffee's brewing hot, and so are the stakes at ACTEC, where 55 new Fellows just got the nod. The American College of Trust and Estate Counsel isn't your average club. They've been at this game since 1949, bringing together the finest minds in trusts and estates. But what does this newest batch bring to the table, and why should investors take a moment to notice? A Diverse...

Continue Reading

Top 5 Most Recently Viewed Articles

Xometry's Teamspace Expansion: A Game Changer for Enterprises

Updated Category News Views 134

Xometry's Innovative Teamspace Expansion for Enterprises Xometry, Inc. (NASDAQ: XMTR), known for its AI-driven marketplace that connects buyers with manufacturers, has officially expanded its Teamspace collaboration solution into Europe, the UK, and Turkey. This exciting development enhances the opportunities available for enterprise customers looking to streamline their...

Continue Reading
Netflix Prepares for Q4 2024 Earnings Announcement

Updated Category News Views 187

Netflix's Upcoming Financial Results Announcement Netflix, Inc. (NASDAQ: NFLX) is gearing up to announce its fourth quarter financial results for 2024. The results, along with the company's business outlook, will be made available on its investor relations website, ensuring transparency for all stakeholders. Investors and interested parties can access the information on...

Continue Reading
Join the Red Cat Holdings Class Action: Steps to Take Now

Updated Category News Views 159

Join the Red Cat Holdings Class Action: Steps to Take Now If you're an investor in Red Cat Holdings, Inc. (NASDAQ: RCAT) and have experienced losses exceeding $100,000, a significant opportunity has arisen for you. The Rosen Law Firm, known for its dedication to investor rights, is spearheading a class action lawsuit against Red Cat Holdings. This initiative is...

Continue Reading
Integer Holdings Corporation Shows Resilience Amid Challenges

Updated Category News Views 87

Integer Holdings Corporation's Steady Market Position Integer Holdings Corporation (NYSE: ITGR) has recently garnered attention from analysts, particularly with Citi maintaining a Neutral rating. The firm has set a price target of $130.00 for the company's stock, reflecting confidence amidst mixed financial performance in Q3 2024. Financial Overview and Revenue...

Continue Reading
Grand Opening of Bridle Park at Alamar by Richmond American

Updated Category News Views 281

Richmond American Marks the Launch of Bridle Park at Alamar Bridle Park at Alamar brings a fresh take on contemporary living, blending resort-style amenities with thoughtfully planned, newly built homes that make day-to-day life feel easy and inviting. A Fresh Addition to the Alamar Masterplan Richmond American Homes, a subsidiary of M.D.C. Holdings, Inc., is introducing...

Continue Reading